TrialSignal
Clinical trial intelligence report
An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01349920
Status
COMPLETED
Phase
N/A
Sponsor
Merck Sharp & Dohme LLC
Executive brief
Investment-Ready Snapshot
This study will evaluate biomarkers that reflect changes in gut mucosal status during therapy with infliximab and determine whether changes in the levels of the selected biomarkers can be used to predict endoscopically assessed gut mucosal status changes.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01349920
Indication
Crohn Disease
Modality
monoclonal antibody
Target
Infliximab
Intervention
Infliximab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.